Compare ARK Genomic Revolution ETF (ARKG) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Broadcom Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Broadcom Inc trades at $393.82 (market cap $1.90T). The key difference: Broadcom Inc pays a 0.65% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Broadcom Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | AVGO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $481.57 |
52-Week Low | $23.09 | $274.38 |
Market Cap | — | $1.90T |
Enterprise Value | — | $1.95T |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Broadcom (AVGO) trades at $399.97, down 0.28% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $2.44 versus $2.40, continuing a pattern of earnings outperformance. Recent news highlights a significant $30 billion Apple chip supply deal extending through 2031, providing substantial revenue visibility for its custom AI silicon operations.
Broadcom presents a compelling growth story driven by AI semiconductor demand and strategic partnerships, with analyst consensus strongly bullish (86% buy ratings) and a $510.43 price target suggesting 28% upside. Key risks include high valuation multiples (P/E 66.55) and dependence on major customers like Apple, though strong cash flow generation ($27.54B operating cash flow in 2025) supports dividend payments and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
